LINC00174: A Long Intergenic Non-Protein Coding RNA (G285908)

Target Name: LINC00174

NCBI ID: G285908

LINC00174

Other Name(s): long intergenic non-protein coding RNA 174 | NCRNA00174 | Long intergenic non-protein coding RNA 174

LINC00174: A Long Intergenic Non-Protein Coding RNA

Non-Protein-Coding RNAs (NP-C RNAs) have emerged as a promising new class of genetic elements in recent years. These RNAs are not composed of amino acids and are not involved in protein synthesis, but they play important roles in various cellular processes. They are involved in gene regulation, DNA replication, and other important cellular processes. LINC00174 is a typical example of an NP-C RNA. In this article, we will discuss the characterization of LINC00174, its potential drug targets, and its potential use as a biomarker.

Characterization of LINC00174

LINC00174 is a 21.1 kilobase (kb) RNA molecule that was identified in the ENCODE database. It is a non-coding RNA and does not contain any amino acids or any information about protein synthesis. The RNA was identified using a variety of computational tools, including RNA-Seq, RNA-seq, and microarray analysis.

Function of LINC00174

LINC00174 is involved in various cellular processes, including gene regulation, DNA replication, and RNA metabolism. It is expressed in various tissues and cells in the body, including brain, heart, and muscle. It is also highly expressed in the placenta, which is a critical organ for fetal development and growth.

One of the most interesting functions of LINC00174 is its role in gene regulation. LINC00174 has been shown to play a role in the regulation of gene expression by binding to specific DNA sequences. This interaction between LINC00174 and DNA sequences allows it to regulate gene expression and contribute to the regulation of various cellular processes.

Potential Drug Targets

LINC00174 has the potential to serve as a drug target due to its unique function in gene regulation. Several studies have suggested that LINC00174 may be a potential drug target for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

One of the reasons for the potential drug target status of LINC00174 is its involvement in the regulation of gene expression. This function of LINC00174 makes it an attractive target for drugs that are designed to disrupt gene expression. For example, drugs that inhibit the activity of LINC00174 may be useful in treating various diseases.

Another potential drug target for LINC00174 is its role in the regulation of DNA replication. LINC00174 has been shown to play a role in the regulation of DNA replication in various cell types. This function of LINC00174 makes it a potential target for drugs that are designed to disrupt DNA replication.

Potential Use as a Biomarker

LINC00174 has the potential to serve as a biomarker for various diseases. Its involvement in the regulation of gene expression and DNA replication makes it an attractive candidate for use as a biomarker for diseases that are characterized by these processes.

For example, LINC00174 may be used as a biomarker for cancer. Cancer is characterized by the regulation of gene expression and DNA replication, and LINC00174 has been shown to play a role in these processes. Therefore, LINC00174 may be an attractive candidate for use as a biomarker for cancer.

Another potential use for LINC00174 as a biomarker is its role in the regulation of neurodegenerative diseases. Neurodegenerative diseases are characterized by the progressive loss of cellular elements and the damage to neural networks. LINC00174 has

Protein Name: Long Intergenic Non-protein Coding RNA 174

The "LINC00174 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00174 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets